Clinical Trial Update: Subcutaneous Olanzapine for Hyperactive or Mixed Delirium [NA]

View source ↗

Summary

A completed clinical trial investigates subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• olanzapine (olanzapine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Cancer | NA | Status: COMPLETED